Entheon Biomedical Corp. provide an update on its Observational Study, EBIQ-101. The results of EBIQ-101 will serve as the foundation for the strategic aims of Entheon IQTM and Entheon IDTM, the development of a framework for characterizing the psychedelic drug state of patients, and to research phenotypes associated with particular addictions and mental health disorders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 CAD | -51.61% |
|
-51.61% | -25.00% |
1st Jan change | Capi. | |
---|---|---|
-25.00% | 487K | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- ENBI Stock
- News Entheon Biomedical Corp.
- Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose